AU
UK
CA
US
IND
NZ
Last update at 2026-06-05T20:17:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Beta Bionics Announces Board Appointment of Gerard Michel
Thu 27 Mar 25, 08:45 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 3.51M | -26.38600M | -47.67800M | -36.50800M | -25.64900M |
| Minority interest | - | - | - | - | - |
| Net income | 2.70M | -26.38600M | -47.67800M | -39.16300M | -26.75700M |
| Selling general administrative | 43.53M | 29.55M | 18.97M | 17.30M | 13.64M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 73.43M | 31.02M | 1.43M | 2.03M | 2.88M |
| Reconciled depreciation | 0.35M | 0.23M | 0.12M | 0.13M | 0.15M |
| Ebit | 3.51M | -12.41000M | -38.18200M | -33.85300M | -24.53100M |
| Ebitda | 3.86M | -12.18100M | -37.78300M | -33.69100M | -24.46300M |
| Depreciation and amortization | 0.35M | 0.23M | 0.40M | 0.16M | 0.07M |
| Non operating income net other | - | - | - | 0.03M | - |
| Operating income | 0.66M | -12.41000M | -38.18200M | -33.85300M | -24.53100M |
| Other operating expenses | 84.57M | 49.62M | 40.25M | 36.57M | 28.09M |
| Interest expense | - | 0.12M | 1.44M | 2.69M | 1.19M |
| Tax provision | 0.81M | 0.00000M | - | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | 2.92M | 0.12M | -2.09900M | -2.68500M | -1.18600M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.81M | - | -0.03989M | 2.65M | 1.11M |
| Total revenue | 85.23M | 37.20M | 2.06M | 2.72M | 3.56M |
| Total operating expenses | 72.77M | 43.43M | 39.61M | 35.89M | 27.41M |
| Cost of revenue | 11.80M | 6.19M | 0.64M | 0.69M | 0.67M |
| Total other income expense net | 2.85M | -13.97600M | -9.49600M | -2.65500M | -1.11800M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 2.70M | -26.38600M | -45.01400M | -36.50800M | -25.64900M |
| Net income applicable to common shares | - | - | - | -36.50800M | -25.64900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 123.63M | 76.59M | 38.61M | 17.86M | 33.12M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 6.50M | 2.53M | 0.94M | 0.10M | 2.74M |
| Total liab | 12.41M | 7.84M | 22.84M | 23.72M | 21.17M |
| Total stockholder equity | 111.22M | 68.75M | 15.78M | -5.85900M | 11.95M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 8.19M | 5.08M | 5.25M | 4.68M | 4.11M |
| Common stock | 0.35M | 0.33M | 0.23M | 0.10M | 0.08M |
| Capital stock | 0.35M | 0.33M | 0.23M | 0.10M | 0.08M |
| Retained earnings | -528.84800M | -531.54800M | -505.16200M | -457.48400M | -420.97600M |
| Other liab | - | - | - | 1.06M | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | 0.00000M | - | - |
| Cash | 43.45M | 32.41M | 12.70M | 7.67M | 22.80M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 10.95M | 6.14M | 16.45M | 14.73M | 5.95M |
| Current deferred revenue | - | - | - | - | 0.17M |
| Net debt | -42.51800M | -31.37400M | -1.66900M | 8.20M | -6.54700M |
| Short term debt | 0.10M | 0.10M | 10.19M | 8.03M | 1.04M |
| Short long term debt | - | - | 10.15M | 7.85M | 0.62M |
| Short long term debt total | 0.94M | 1.04M | 11.03M | 15.87M | 16.25M |
| Other stockholder equity | 639.14M | 599.88M | 515.03M | 451.61M | 432.83M |
| Property plant equipment | - | - | - | 1.42M | 1.97M |
| Total current assets | 119.53M | 73.76M | 37.16M | 16.16M | 31.15M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | -5.85900M | 11.95M |
| Short term investments | 47.58M | 20.82M | 19.81M | - | - |
| Net receivables | 11.74M | 11.06M | 0.39M | 0.37M | 0.04M |
| Long term debt | - | - | - | 7.84M | 15.01M |
| Inventory | 10.25M | 6.93M | 3.32M | 2.00M | 1.41M |
| Accounts payable | 2.66M | 0.96M | 1.01M | 2.02M | 0.64M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.57M | 0.08M | 0.14M | -0.08300M | 0.02M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.10M | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -457.48400M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | -0.00000M | 0.28M | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4.10M | 2.83M | 1.45M | 1.71M | 1.97M |
| Capital lease obligations | 0.94M | 1.04M | 0.04M | 0.19M | 0.62M |
| Long term debt total | - | - | - | 7.84M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -25.04300M | -0.98100M | -0.03900M | -0.20900M | -0.14300M |
| Change to liabilities | - | - | - | 2.42M | -3.56300M |
| Total cashflows from investing activities | -26.59000M | -0.98100M | -19.70900M | -0.20900M | -0.14300M |
| Net borrowings | 0.00000M | -10.61000M | -6.31300M | -0.71400M | 14.44M |
| Total cash from financing activities | 15.05M | 39.41M | 51.78M | 10.14M | 20.82M |
| Change to operating activities | - | - | - | 1.40M | -1.65700M |
| Net income | 2.70M | -26.38600M | -47.67800M | -36.50800M | -25.64900M |
| Change in cash | 11.04M | 19.72M | 0.87M | -15.13100M | -1.80300M |
| Begin period cash flow | 32.41M | 12.70M | 11.82M | 26.95M | 28.76M |
| End period cash flow | 43.45M | 32.41M | 12.70M | 11.82M | 26.95M |
| Total cash from operating activities | 22.52M | -18.68100M | -31.25100M | -24.95000M | -22.60400M |
| Issuance of capital stock | 0.48M | 7.02M | 29.04M | 10.86M | 0.00000M |
| Depreciation | 0.35M | 0.23M | 0.13M | 0.13M | 0.15M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | 51.78M | - | - |
| Change to inventory | -3.31900M | -3.61100M | -1.32400M | -0.58700M | -0.55700M |
| Change to account receivables | -0.85400M | -10.64900M | 0.12M | -0.32200M | 0.01M |
| Sale purchase of stock | -6.00000M | 0.25M | 0.12M | 10.86M | - |
| Other cashflows from financing activities | 15.05M | 43.00M | 35.01M | -0.20900M | 20.82M |
| Change to netincome | - | - | - | 0.16M | 8.34M |
| Capital expenditures | 1.55M | 0.56M | 0.06M | 0.21M | 0.14M |
| Change receivables | - | - | - | -0.32200M | - |
| Cash flows other operating | - | - | - | 8.99M | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -15.01600M | - |
| Change in working capital | -3.06900M | -15.52100M | -0.90600M | 2.11M | -5.76400M |
| Stock based compensation | 24.23M | 9.77M | 8.15M | 7.94M | 7.83M |
| Other non cash items | -1.69600M | 13.23M | 9.05M | 1.37M | 0.83M |
| Free cash flow | 20.97M | -19.24000M | -31.30900M | -25.15900M | -22.74700M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems Inc |
-0.12 1.11% | 10.67 | 152.29 | 25.77 | 4.35 | 3.38 | 3.35 | 282.74 |
| ABT Abbott Laboratories |
0.29 0.32% | 91.07 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
4.45 1.48% | 305.66 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-0.26 0.32% | 81.67 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.3 0.61% | 48.55 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
566 Queensbury Avenue, Queensbury, NY, United States, 12804
| Name | Title | Year Born |
|---|---|---|
| Mr. Gerard J. Michel MBA, MS | CEO & Director | 1963 |
| Mr. John Purpura M.S. | Chief Operating Officer | 1961 |
| Dr. Johnny John M.D. | Sr. VP Clinical Devel. & Medical Affairs | 1964 |
| Mr. Anthony C. Dias | VP of Fin. | 1967 |
| Mr. David Hoffman | Gen. Counsel, Corp. Sec. & Chief Compliance Officer | NA |
| Mr. Robin Wagge | Sr. VP of Rubenstein Associates | NA |
| Mr. Kevin Muir | VP of Commercial Operations | NA |
| Dr. Johnny John M.D. | Senior Vice President of Clinical Operations & Medical Affairs | 1965 |
| Ms. Sandra Pennell | Senior VP of Finance and Principal Financial & Accounting Officer | 1979 |
| Dr. Martha S. Rook Ph.D. | Chief Operating Officer | 1972 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...